Keyword: Otezla

Expanding Otezla's market to scalp psoriasis could be challenging for Celgene, in light of hurdles such as mounting competition.

Merck and J&J presented numbers suggesting pharma faces increased pricing pressure, but one analyst is skeptical.

The departure of Celgene COO Scott Smith wasn't entirely surprising, given recent setbacks, including a delayed FDA decision on the company's MS candidate ozanimod.

Despite struggles in 2017, Celgene turned in 16% annual sales growth, buoyed by key drugs Revlimid, Pomalyst and Otezla.

Good news for pharma's pricing power: The pitched battle over sticker prices is mostly confined to a few therapeutic areas, a new analysis shows.

SAN FRANCISCO—Looking to recover from a tough year, Celgene rolled out its 2018 guidance at the J.P. Morgan Healthcare conference in San Francisco.

Celgene on Thursday reported third-quarter financial results that further spooked investors.

Celgene on Monday reported a 2016 EPS beat and rolled out its guidance for 2017.

Novartis’ Cosentyx and Celgene’s Otezla aren’t just battling it out in the psoriasis arena. As of early this year, they’re competing in psoriatic arthritis, too—and each drugmaker made its case this week with new data in that disease.

Celgene’s Otezla is picking up steam in the U.K. Shortly after winning NICE support in severe psoriasis, it now boasts an initial backing in psoriatic arthritis--and the fact that it's a pill made all the difference.